ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis
Overall, our study highlights the potential clinical application of ICOS as a promising strategy for combating TNBC recurrence and metastasis.
Authors
- Tao Zeng (ORCID: https://orcid.org/0000-0002-0295-3994)
- Lixue Cao (ORCID: https://orcid.org/0000-0002-0486-6587)
- Xinxin Chen (ORCID: https://orcid.org/0000-0002-5513-3332)
- Baijin Xia
- Fei Yu (ORCID: https://orcid.org/0000-0003-1546-9365)
- Hui Zhang (ORCID: https://orcid.org/0000-0003-3620-610X)
- Haojie Peng (ORCID: https://orcid.org/0009-0009-4301-5214)
- Haiyan Ye (ORCID: https://orcid.org/0000-0003-1081-5708)
- Yanzhen Chen (ORCID: https://orcid.org/0000-0002-9659-4880)
- Jialing Guo
Institutions
- Sun Yat-sen University (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- Guangdong Academy of Medical Sciences (CN)
- Guangdong Provincial People's Hospital (CN)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1136/jitc-2024-010028
- Citations
- 8
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- National Natural Science Foundation of China
- Guangdong Provincial People's Hospital
- Basic and Applied Basic Research Foundation of Guangdong Province